West Pharmaceutical Services, Inc. WST
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.69% | 13.80% | 21.05% | 7.51% | 7.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.69% | 13.80% | 21.05% | 7.51% | 7.73% |
| Cost of Revenue | 3.29% | 10.25% | 17.68% | 5.45% | 5.83% |
| Gross Profit | 18.04% | 20.19% | 27.81% | 11.07% | 11.18% |
| SG&A Expenses | 7.62% | 18.52% | 14.90% | 29.05% | 23.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -633.33% | 400.00% | -833.33% | -- | -50.00% |
| Total Operating Expenses | 3.78% | 11.51% | 16.21% | 9.32% | 8.38% |
| Operating Income | 26.22% | 22.50% | 42.42% | 1.40% | 5.46% |
| Income Before Tax | 56.32% | 14.94% | 61.11% | -0.90% | 3.33% |
| Income Tax Expenses | 70.59% | 6.62% | 85.48% | -9.51% | 4.94% |
| Earnings from Continuing Operations | 52.86% | 16.84% | 54.57% | 1.54% | 2.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.86% | 16.84% | 54.57% | 1.54% | 2.94% |
| EBIT | 26.22% | 22.50% | 42.42% | 1.40% | 5.46% |
| EBITDA | 22.39% | 20.26% | 35.45% | 4.09% | 5.75% |
| EPS Basic | 56.76% | 19.15% | 55.64% | 2.10% | 3.80% |
| Normalized Basic EPS | 28.90% | 23.15% | 41.31% | 2.82% | 6.65% |
| EPS Diluted | 57.29% | 18.13% | 56.10% | 2.08% | 3.78% |
| Normalized Diluted EPS | 28.87% | 22.80% | 41.49% | 3.10% | 6.94% |
| Average Basic Shares Outstanding | -2.49% | -1.94% | -0.69% | -0.55% | -0.82% |
| Average Diluted Shares Outstanding | -2.48% | -1.66% | -0.82% | -0.82% | -1.09% |
| Dividend Per Share | 4.76% | 4.76% | 4.76% | 4.76% | 5.00% |
| Payout Ratio | -0.33% | -0.11% | -0.33% | 0.02% | 0.01% |